Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Degludec Dosing and Titration in T2DM
NCT01880736Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2013
- Primary completion
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin degludec in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change From Baseline in HbA1c at 26 weeks. Started Jun 2013; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01880736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01880736.